Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNA2 | P20248 | 2/20 | 0.35 |
| ▸ | CDK2 | P24941 | 2/20 | 0.35 |
| ▸ | CCNA1 | P78396 | 2/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | EDNRA | P25101 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6335220 | 0.94 | CCNA2 (0.38) | CCNA2CDK2CCNA1TSHR | |
| SCHEMBL6334299 | 0.90 | EDNRA (0.32) | EDNRA | |
| SCHEMBL6345044 | 0.90 | TSHR (0.31) | TSHREDNRA | |
| SCHEMBL6343010 | 0.86 | CCNA2 (0.43) | CCNA2CDK2CCNA1TSHRMEN1 | |
| SCHEMBL6333878 | 0.86 | CCNA2 (0.39) | CCNA2CDK2CCNA1TSHRMEN1 | |
| SCHEMBL6403920 | 0.82 | CCNA2 (0.37) | CCNA2CDK2CCNA1 | |
| SCHEMBL6335241 | 0.80 | MEN1 (0.35) | CCNA2CDK2CCNA1TSHRMEN1 | |
| SCHEMBL6342501 | 0.80 | TSHR (0.31) | TSHR | |
| SCHEMBL6344025 | 0.80 | CCNA2 (0.43) | CCNA2CDK2CCNA1TSHRMEN1 | |
| SCHEMBL6335444 | 0.79 | CCNA2 (0.39) | CCNA2CDK2CCNA1TSHRMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050171350-A1 | Benzhydryl derivatives | FUJISAWA PHARAMACEUTICAL CO., LTD. (JP) | 2005-08-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050171350-A1 | Benzhydryl derivatives | BDKRB1, BDKRB2, TACR1 | CCNA2 2233/4885CDK2 2274/4885CCNA1 1534/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.